- Published on
Medicine – Chronic Lymphocytic Leukaemia (CLL)
Chronic lymphocytic leukaemia (CLL) is a mature B-cell lymphoproliferative malignancy characterised by the progressive accumulation of clonal, usually small and mature-appearing lymphocytes in the peripheral blood, bone marrow and lymphoid tissues.
CLL is typically an indolent leukaemia and is one of the most common leukaemias affecting older adults in Western populations.
Many patients remain asymptomatic for years and do not require immediate treatment.
CLL commonly presents as an incidental finding of persistent lymphocytosis in an older adult. The characteristic peripheral blood film shows small mature-looking lymphocytes and smudge cells.
1. Pathophysiology
CLL develops from the clonal expansion and accumulation of mature B lymphocytes.
These cells have impaired apoptosis and receive survival signals from the surrounding tissue microenvironment.
Malignant lymphocytes may accumulate within:
- Peripheral blood.
- Bone marrow.
- Lymph nodes.
- Spleen.
- Liver.
Pathophysiology Flowchart
2. Clinical Features
A. Incidental Diagnosis
Many patients are diagnosed incidentally when routine blood investigations reveal an elevated lymphocyte count.
CLL may remain asymptomatic for prolonged periods.
B. Persistent Lymphocytosis
Persistent absolute lymphocytosis is a characteristic finding.
The diagnostic threshold for CLL is generally at least 5 × 109/L clonal B lymphocytes in peripheral blood for at least three months, confirmed by flow cytometry.
A lower clonal B-cell count without other disease features may represent monoclonal B-cell lymphocytosis (MBL).
C. Lymphadenopathy
Lymphadenopathy may develop as malignant lymphocytes accumulate within lymph nodes.
Typical features include:
- Painless lymph node enlargement.
- Rubbery lymph nodes.
- Cervical lymphadenopathy.
- Axillary lymphadenopathy.
- Inguinal lymphadenopathy.
D. Hepatosplenomegaly
Splenomegaly and hepatomegaly may occur with increasing disease burden.
Patients may experience abdominal fullness or early satiety.
E. Bone Marrow Failure
Advanced marrow infiltration may cause:
- Anaemia: Fatigue, pallor and dyspnoea.
- Thrombocytopenia: Bruising or bleeding.
- Neutropenia: Increased susceptibility to infection.
F. Other Manifestations
- Recurrent infections due to hypogammaglobulinaemia and immune dysfunction.
- Autoimmune haemolytic anaemia.
- Immune thrombocytopenia.
- Constitutional symptoms, including fever, night sweats and weight loss.
- Fatigue and reduced exercise tolerance.
3. Peripheral Blood Film
The classical peripheral blood film demonstrates small, mature-looking lymphocytes with clumped chromatin and smudge cells (smear cells).
Characteristic Blood Film Findings
- Increased numbers of small lymphocytes.
- Round nuclei with densely clumped chromatin.
- Scant cytoplasm.
- Smudge cells caused by disruption of fragile lymphocytes during smear preparation.
Blood Film Schematic
Simplified educational illustration; not an actual peripheral blood film.
4. Investigations and Diagnosis
| Investigation | Typical Finding or Purpose |
|---|---|
| Full blood count | Persistent absolute lymphocytosis |
| Peripheral blood film | Small mature lymphocytes and smudge cells |
| Flow cytometry | Confirms clonal B-cell population |
| Immunophenotyping | Typically CD19+, CD5+, CD23+, with weak CD20 and surface immunoglobulin |
| FISH / molecular testing | Identifies prognostic and treatment-relevant abnormalities |
| Immunoglobulin levels | May show hypogammaglobulinaemia |
| Direct antiglobulin test | Assesses suspected autoimmune haemolysis |
| Bone marrow biopsy | Not routinely required for diagnosis |
Important Molecular Findings
- del(13q): Often associated with a more favourable prognosis when isolated.
- Trisomy 12: Intermediate or variable prognostic significance.
- del(11q): Historically associated with more aggressive disease.
- del(17p) or TP53 mutation: High-risk disease and important for treatment selection.
- IGHV mutation status: Important prognostic and treatment-selection marker.
Diagnostic Flowchart
5. Staging of CLL
Two commonly used staging systems are the Rai and Binet classifications.
A. Rai Staging
| Stage | Clinical Findings |
|---|---|
| 0 | Lymphocytosis only |
| I | Lymphocytosis with lymphadenopathy |
| II | Lymphocytosis with splenomegaly and/or hepatomegaly |
| III | Disease-related anaemia (haemoglobin below 11 g/dL) |
| IV | Disease-related thrombocytopenia (platelets below 100 × 109/L) |
B. Binet Staging
| Stage | Criteria |
|---|---|
| A | Fewer than three involved lymphoid areas, without anaemia or thrombocytopenia |
| B | Three or more involved lymphoid areas, without anaemia or thrombocytopenia |
| C | Haemoglobin below 10 g/dL and/or platelets below 100 × 109/L attributable to disease |
6. Management
Not every patient with CLL requires treatment.
A. Active Surveillance (Watchful Waiting)
Asymptomatic patients without active or progressive disease are usually managed with observation.
Follow-up includes:
- Periodic clinical assessment.
- Monitoring lymph node and spleen enlargement.
- Full blood counts.
- Assessment for constitutional symptoms and complications.
Early treatment has not demonstrated an overall survival benefit for most asymptomatic patients who do not meet established treatment criteria.
B. Indications for Treatment
Treatment is considered for active or progressive disease, including:
- Progressive bone marrow failure.
- Massive, symptomatic or progressive lymphadenopathy.
- Massive, symptomatic or progressive splenomegaly.
- Rapidly progressive lymphocytosis meeting established criteria.
- Significant constitutional symptoms attributable to CLL.
- Autoimmune cytopenias poorly responsive to standard therapy.
- Symptomatic extranodal disease.
C. Modern Targeted Therapy
Contemporary CLL treatment commonly uses targeted agents selected according to TP53 status, comorbidities, treatment goals and local availability.
| Drug Class | Examples |
|---|---|
| BTK inhibitors | Acalabrutinib, zanubrutinib, ibrutinib |
| BCL2 inhibitor | Venetoclax |
| Anti-CD20 antibodies | Obinutuzumab, rituximab |
Venetoclax-based therapy requires careful assessment and prevention of tumour lysis syndrome.
D. Historical Treatments
Traditional treatment options included:
- Observation without immediate therapy.
- Chlorambucil: An oral alkylating chemotherapy agent.
- Radiotherapy: Occasionally used for local symptom control.
Chlorambucil is no longer a preferred first-line option for most patients where modern targeted treatments are available. Radiotherapy has a limited, mainly palliative role.
Management Flowchart
7. Important Complications
A. Recurrent Infections
CLL-associated immune dysfunction and hypogammaglobulinaemia increase susceptibility to infections.
B. Autoimmune Cytopenias
Autoimmune haemolytic anaemia and immune thrombocytopenia may occur.
C. Richter Transformation
Richter transformation refers to the development of an aggressive lymphoma, most commonly diffuse large B-cell lymphoma, in a patient with CLL.
It should be suspected when there is:
- Rapidly enlarging lymphadenopathy.
- New constitutional symptoms.
- Markedly elevated LDH.
- Sudden clinical deterioration.
8. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Disease | Mature B-cell lymphoproliferative malignancy |
| Typical age | Older adults |
| Clinical course | Often indolent |
| Common presentation | Incidental lymphocytosis |
| Blood film | Small mature lymphocytes and smudge cells |
| Immunophenotype | CD5+, CD19+, CD23+ |
| Diagnostic threshold | ≥5 × 109/L clonal B cells for ≥3 months |
| Organ involvement | Lymph nodes, spleen, liver, bone marrow |
| Immune complication | Hypogammaglobulinaemia |
| Autoimmune complication | Autoimmune haemolytic anaemia |
| Transformation | Richter transformation |
| Initial management | Watchful waiting if asymptomatic and inactive |
| Modern treatment | Targeted agents, including BTK or BCL2 inhibitors |
9. Key Examination Pearls
- CLL is a typically indolent mature B-cell malignancy affecting older adults.
- Many cases are discovered incidentally following routine blood tests.
- Persistent lymphocytosis is a characteristic laboratory finding.
- Small mature-appearing lymphocytes and smudge cells are typical blood film findings.
- CD5 and CD23 coexpression on clonal B cells is characteristic.
- Lymphadenopathy, hepatosplenomegaly and marrow failure may develop with progression.
- Hypogammaglobulinaemia predisposes to recurrent infections.
- Autoimmune haemolytic anaemia is a recognised complication.
- Richter transformation produces a more aggressive lymphoma.
- Asymptomatic CLL usually does not require immediate treatment.
- Modern treatment primarily involves targeted therapies rather than chlorambucil.
An older patient with incidentally discovered persistent lymphocytosis, small mature lymphocytes and smudge cells on peripheral blood film should raise suspicion of chronic lymphocytic leukaemia. Confirm the diagnosis using peripheral blood flow cytometry.
Rapid lymph node enlargement, severe cytopenias, serious infections or new constitutional symptoms warrant prompt haematological assessment. Treatment should be individualised by a specialist haematology team.
Kembara Xtra – Medicine Revision Notes